Levitra
ApprovedSmall molecule
BayerLevitra is one of 124 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.
5
Indications
39
Total Trials
0
Active Trials
123
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
154 competitors in Pulmonary Hypertension
#DrugCompanyPhaseTrials
1Reata
BiogenPhase 3
Diamox
TevaPhase 3
Lexapro
AbbViePhase 3
Crestor
AstraZenecaPhase 3
Levitra
BayerApproved
Accrufer
SShield Therapeutics
Phase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Distilled Water
GSKPhase 3
Diluent
SanofiPhase 3
Myrbetriq
AstellasPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Erectile Dysfunction24 trials
Show 21 more trials
Treatment2 trials
Satisfaction2 trials
9 more indications
Benign Prostatic Hyperplasia1 trial
Prostatectomy1 trial
TED1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levitra. EMBL-EBI & Wellcome Sanger Institute.
- [4]